Biopharmaceutical companies increase R&D investment
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
After the Spring Festival, as the veterinary raw material drug market rose to a high level, the market began to weaken, and the veterinary raw material drug market showed a downward trend. However, with the arrival of the peak season for traditional demand, the veterinary raw material drug market may rebound.
Among the Veterinary Raw Materials monitored by the China Veterinary Drug and Feed Trading Center, the market prices of many varieties have dropped significantly.

However, with the advent of summer, the market trend of veterinary drug raw materials may usher in a wave of rebound, and the prices of some products may enter an upward channel.
First, the veterinary raw material drug market is about to enter the peak season of traditional demand, and the downstream market demand is gradually increasing. The rigid demand restricts the downside of the raw material drug market.
Second, the cumulative increase in external factors, environmental protection, security inspections and other factors may cause some companies to restrict or even stop production, and the supply of veterinary raw materials in the veterinary drug market has tightened. The upstream raw material plant of FLORFENICOL has been suspended due to environmental protection. Recently, the news has been released. The florfenicol plant has a high price mentality, and the market has responded positively and focused attention.
Third, the summer high temperature maintenance season is coming. Historical data shows that the high temperature maintenance of mainstream manufacturers will have a greater impact on product market prices.
Fourth, the early-stage demand has weakened, shipments are not smooth, intermediate channels have reduced prices for shipments, withdrawn funds, some channels have been oversold, and inventories have dropped to low levels. Once market demand improves, full replenishment of the industry chain will be triggered, which may be promoted by then Product prices are rising rapidly.
Looking for chemical products? Let suppliers reach out to you!
2026-06-20
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Can China's Biomedical Industry Revolutionize Healthcare with Innovation and Growth?
-
The 2022 edition of the list of the world's top 2 percent scientists has been announced: Dr. Liu Yongjun, president of Cinda Bio, is on it!
-
Three Chains Fusion' of Zhuhai Biomedical Industry
-
135 biomedical companies forecast nearly 60% year-on-year growth
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
4 Pharma Firms Lose Licenses in Jammu and Kashmir Amid Illegal Drug Sales Crackdown
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
Recommend Reading
-
BASF Raises API and Excipient Prices
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
IPEC Updates Excipient Qualification Guidance
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Supply Contraction Supports Melamine Market Stability with Fluctuations in China
-
On September 2nd, the Chinese acetone market continued to decline
-
On March 18, the Chinese epichlorohydrin market continued to decline
-
August Ethyl Acetate Prices Show Fluctuating Decline in China
-
Sika Impacted by Weaker Dollar in H1, Lowers Full-Year Sales Guidance